A.R.T. Advisors’s Sierra Oncology, Inc. Common Stock SRRA Stock Holding History

A.R.T. Advisors’s Portfolio SRRA Stock Details SRRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-970	Closed	-$22K	–	1837
2019 Q2	$22K	Buy	970 +635	+190%	+$30.8K	﹤0.01%	1294
2019 Q1	$23K	Buy	+335	New	+$21.5K	﹤0.01%	1250
2018 Q4	–	Sell	-677	Closed	-$46K	–	1785
2018 Q3	$46K	Buy	+677	New	+$61.4K	﹤0.01%	1322
2018 Q2	–	Sell	-372	Closed	-$30K	–	1872
2018 Q1	$30K	Buy	+372	New	+$42.2K	﹤0.01%	1429
2017 Q4	–	Sell	-567	Closed	-$35K	–	1770
2017 Q3	$35K	Buy	+567	New	+$33.3K	﹤0.01%	1274
2017 Q1	–	Sell	-258	Closed	-$15K	–	1802
2016 Q4	$15K	Buy	+258	New	+$16.1K	﹤0.01%	1252
2016 Q3	–	Sell	-303	Closed	-$24K	–	1302
2016 Q2	$24K	Sell	303 -100	-25%	-$19.1K	﹤0.01%	1294
2016 Q1	$108K	Buy	403 +105	+35%	+$33.5K	﹤0.01%	1248
2015 Q4	$178K	Buy	+298	New	+$202K	0.01%	1251

Other funds holding SRRA

Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return

NLVP

New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return

Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

A.R.T. Advisors's SRRA Position: Q3 2019 in Review

A.R.T. Advisors sold out of Sierra Oncology, Inc. Common Stock (SRRA) in Q3 2019, closing a stake of 970 shares — an estimated $22K sold.

A.R.T. Advisors first reported a position in SRRA in Q4 2015 and held it in 9 quarters. The position peaked at $178K in Q4 2015. 45 funds tracked by Wall St. Rank hold SRRA as of Q3 2019.

A.R.T. Advisors reported no remaining Sierra Oncology, Inc. Common Stock position as of Q3 2019 after selling out during the quarter.
A.R.T. Advisors sold 970 Sierra Oncology, Inc. Common Stock shares in Q3 2019, an estimated $22K.
A.R.T. Advisors first reported a position in Sierra Oncology, Inc. Common Stock in Q4 2015 and held it in 9 quarters.
A.R.T. Advisors's Sierra Oncology, Inc. Common Stock position peaked at $178K in Q4 2015.
45 funds tracked by Wall St. Rank held Sierra Oncology, Inc. Common Stock as of Q3 2019.

Based on A.R.T. Advisors's 13F filing for Q3 2019, filed 14 Nov 2019.